Q32 Bio Inc (QTTB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Q32 Bio Inc (QTTB) has a cash flow conversion efficiency ratio of -0.029x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.08 Million) by net assets ($105.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see QTTB market cap overview for the company's overall valuation and market capitalisation.
Q32 Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Q32 Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Q32 Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q32 Bio Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Q32 Bio Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mountain Lake Acquisition Corp. II Class A Ordinary Shares
NASDAQ:MLAA
|
N/A |
|
Darfon Electronics Corp
TW:8163
|
-0.023x |
|
Pioneer Acquisition I Corp Class A Ordinary Shares
NASDAQ:PACH
|
-0.001x |
|
Oxley Bridge Acquisition Limited Class A Ordinary Shares
NASDAQ:OBA
|
0.000x |
|
COG Financial Services Ltd
AU:COG
|
0.198x |
|
Asflow Co. Ltd.
KQ:159010
|
-0.025x |
|
TQM CORPORATION
BK:TQM-R
|
0.088x |
|
CPI Card Group Inc
NASDAQ:PMTS
|
-2.484x |
Annual Cash Flow Conversion Efficiency for Q32 Bio Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Q32 Bio Inc from 2016 to 2025. View QTTB live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $42.01 Million | $-33.54 Million | -0.798x | +93.31% |
| 2024-12-31 | $5.67 Million | $-67.72 Million | -11.932x | -11786.26% |
| 2023-12-31 | $-182.92 Million | $-18.68 Million | 0.102x | +265.87% |
| 2022-12-31 | $178.00 Million | $-10.96 Million | -0.062x | +90.48% |
| 2021-12-31 | $169.65 Million | $-109.75 Million | -0.647x | -34.41% |
| 2020-12-31 | $196.00 Million | $-94.33 Million | -0.481x | -36.19% |
| 2019-12-31 | $258.51 Million | $-91.36 Million | -0.353x | -63.04% |
| 2018-12-31 | $196.35 Million | $-42.56 Million | -0.217x | -428.91% |
| 2017-12-31 | $98.31 Million | $6.48 Million | 0.066x | +105.83% |
| 2016-12-31 | $7.50 Million | $-8.48 Million | -1.131x | -- |
About Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical t… Read more